Jc. Cervellino et al., CISPLATIN AND IFOSFAMIDE IN PATIENTS WITH ADVANCED SQUAMOUS-CELL CARCINOMA OF THE UTERINE CERVIX - A PHASE-II TRIAL, Acta oncologica, 34(2), 1995, pp. 257-259
Thirty patients with advanced squamous cell carcinoma of the cervix we
re included in a phase II study with cisplatin (DDP) and ifosfamide (I
F)/mesna. They received a median of 4 courses of chemotherapy and were
all evaluable for response and toxicity. Each cycle consisted of 2 50
0 mg/m(2) IF i.v. days 1-5; mesna 500 mg/m(2) i.v. at hours 0 and 2, a
nd 1 000 mg/m(2) per os at hours 6 and 10, days 1-5; DDP 20 mg/m(2) i.
v., days 1-5. Cycles were repeated every 4 weeks. One patient obtained
CR and 14 PR giving an overall response rate of 50%. Mean duration of
response was 21 months. Anemia grade 3 developed in 7 patients, leuko
penia grade 3 in 9 patients and grade 4 in one patient; thrombopenia g
rade 3 in 2; creatinine clearance grade 3 in one; CNS grade 3 in one a
nd cystitis grade 3 in one patient. Overall median survival time was a
bout 25+ months (3-63+); after a follow-up of 70 months, 11 patients (
37%) are still alive with a median survival of 31+ months. IF plus DDP
seems to be a good combination for treatment of advanced cervical can
cer, with acceptable tolerance and response rate.